Last update 01 Nov 2024

STEAP1 x Tubulin

Basic Info

Related Targets
STEAP1Tubulin

Related

1
Drugs associated with STEAP1 x Tubulin
Vandortuzumab vedotin
Target
STEAP1 x Tubulin
Mechanism
STEAP1 inhibitors [+3]
Active Org.-
Originator Org.
Genentech, Inc.Genentech, Inc.
Active Indication-
Inactive Indication
Metastatic castration-resistant prostate cancer [+1]
Drug Highest PhaseDiscontinued
First Approval Ctry. / Loc.-
First Approval Date20 Jan 1800
1
Clinical Trials associated with STEAP1 x Tubulin
NCT01283373 / CompletedPhase 1
A Phase I, Open-Label Study of the Safety and Pharmacokinetics of Escalating Doses of DSTP3086S in Patients With Metastatic Castration-Resistant Prostate Cancer
100 Clinical Results associated with STEAP1 x Tubulin
Login to view more data
100 Translational Medicine associated with STEAP1 x Tubulin
Login to view more data
0 Patents (Medical) associated with STEAP1 x Tubulin
Login to view more data

Analysis

Perform a panoramic analysis of this field.
login
or
view full example data
Perform a panoramic analysis of this field.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free